As this review was in preparation, H. Lundbeck A/S announced halting a trial based on an interim futility analysis of the effects of their PDE10A inhibitor Lu AF11167 against persistent prominent negative symptoms in patients with schizophrenia (BNSS). The gene discussed is PDE10A; the disease is schizophrenia.